Earnings in Focus: Scotts Miracle-Gro (SMG), AbbVie Inc. (ABBV), Earth Science Tech Inc (ETST)
Scotts Miracle-Gro (NYSE: SMG) showing dropped of -0.10% and closed at $92.14, after gaining total volume of 329,917.00 shares. Its earnings per share (EPS) is $59.84 and its beta value stands at 0.64 points and has total market capitalization of $5.53 billion and a total of 59.84 million outstanding shares.
Scotts Miracle-Gro (SMG) on March 20, 2017 announced more than 100 non-profit organizations nationwide will receive 2017 GRO1000 Grassroots Grants. The organizations awarded will use the funding to improve their communities through the development of public gardens and greenspaces.
Now in its seventh year, the GRO1000 Grassroots Grants are part of The Scotts Miracle-Gro Foundation’s support to bring gardens and greenspaces to more people and communities, particularly to those in need. GRO1000 will support the creation of more than 1,000 community greenscapes by 2018, which aligns with The Scotts Miracle-Gro Company’s 150th anniversary.
“Helping communities across the country experience the powerful benefits of gardening and its ability to transform lives is a privilege for The Scotts Miracle-Gro Foundation,” said Foundation President and Board Member Jim King, who also serves as SVP and Chief Communications Officer for ScottsMiracle-Gro. “As we look forward to the final year of the GRO1000 program, we are committed now, more than ever, to connecting more communities to these benefits.”
From children’s learning gardens to pollinator habitats, urban farms to healing gardens, GRO1000 has supported over 830 community-based projects nationwide since 2011. Projects have resulted in more than 10.7 million square feet of greenspace revitalized, more than 266,000 pounds of produce donated annually and more than 65,000 youth positively impacted through hands-on experiences with nature, according to data collected from previous GRO1000 Grassroots Grants recipients. A full list of this year’s recipients can be found at www.GRO1000.com.
In addition to the Grassroots Grants, The Scotts Miracle-Gro Foundation and its national partners, the U.S. Conference of Mayors, Plant A Row for the Hungry, the Garden Writers Association Foundation, KidsGardening.org, and Franklin Park Conservatory and Botanical Gardens, are building public community gardens and greenspaces in New Bedford, Mass.; New Haven, Conn.; Rochester Hills, Mich.; and Santa Monica, Calif., in 2017. More information on the GRO1000 program can be found at www.GRO1000.com.
AbbVie Inc. (NYSE:ABBV) increased 0.17% closed at $65.80 and traded with total volume of 4.25 million shares, while the average trading remained 7.13 million shares. During last trade its minimum price was $65.56 and it gained the highest price of $66.01. Its market capitalization was $104.55 billion.
AbbVie Inc. (ABBV) on March 14, 2017 announced that priority review has been granted by the Japanese Ministry of Health, Labour and Welfare (MHLW) for its investigational, pan-genotypic, ribavirin-free regimen of glecaprevir/pibrentasvir (G/P) for the treatment of all major genotypes (GT1-6) of the chronic hepatitis C virus (HCV). This priority review follows European Medicines Agency (EMA) accelerated assessment and U.S. Food and Drug Administration (FDA) priority review designations in December 2016 and January 2017 respectively.
“We will work closely with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) as part of our commitment to provide a potential cure for as many people living with HCV as possible,” said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. “We are pleased that G/P has now been recognized as a potential important therapy for people living with HCV through the receipt of priority review designations by regulatory authorities in Japan, the EU and the U.S.”
The Japanese MHLW designates priority review to certain medicines based on the clinical usefulness of the treatment and severity of the disease. Japan has one of the highest rates of hepatitis C infection in the industrialized world, with approximately 1 million people living with the disease, 99 percent of whom are infected with genotype 1 (GT1) or genotype 2 (GT2).1,2 If approved, G/P may provide a shorter, eight week treatment duration for GT1 and GT2 patients without cirrhosis, who make up the majority of HCV patients, and an additional treatment option for genotypes 3-6 patients. G/P is also intended to address the needs of patients with specific treatment challenges, including those with severe chronic kidney disease (CKD) and those not cured with previous DAA (direct-acting antiviral) treatment.
Earth Science Tech Inc (OTCMKTS:ETST) reported the up of 5.24% and closed at $2.04, with the total traded volume of 23,859.00 million shares. During last trade its minimum price was $111,291.00 and it gained its highest price of $2.09 and has a total of 40.91 million outstanding shares.
Earth Science Tech, Inc., a biotechnology company, focuses on delivering nutraceuticals, bioceuticals, and dietary supplements in the areas of health, wellness, sports, and alternative medicine worldwide. It focuses on non-prescription nutritional and dietary supplements for the treatment of chronic pain, joint pain, inflammation, seizures, high blood pressure, memory loss, depression, weight management, nausea, aging, and overall wellness. The company also provides consulting services to the athletic facilities industry. Its marketing services include direct marketing, search engine optimization, public relations, email marketing, social media marketing, and development of referral programs. In addition, Earth Science Tech, Inc. retails health and wellness brands, as well as sports nutrition and dietary supplement products; and stocks and sells high grade cannabidiol rich hemp oil and products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in April 2014. The company was incorporated in 2010 and is headquartered in Boca Raton, Florida.